FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.
What happened
FDA reviewed https://www.alanmeds.com in December 2025 and saw that it offers compounded semaglutide and tirzepatide drug products. FDA says pictured labels identify “Alan” in a way that suggests Alan is the compounder, when FDA says it is not. FDA calls the labeling and advertising false or misleading, so the drugs are misbranded (falsely labeled or advertised) and were introduced into interstate commerce.
What FDA found
Website labels for compounded semaglutide and tirzepatide name “Alan,” suggesting Alan is the compounder even though FDA says it is not.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)The website’s advertising and promotion of these compounded drugs are false or misleading for the same reason.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]The misbranded compounded drugs were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering or offering to deliver them, is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, send OCQC in CDER’s Office of Compliance a written response describing steps taken, including identifying the entities that produce the compounded products, providing sample labeling, and addressing or correcting other website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounders whose drugs are sold under another company’s brand
- online marketers and pharmacies using white-label drug labels
This is a summary. Read the original letter on fda.gov.